APM
NRIX icon

Avidity Partners Management’s Nurix Therapeutics NRIX Stock Holding History

Avidity Partners Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$1.64M – 113
2020
Q4 		$1.64M Hold
50,000
– – 0.05% 93
2020
Q3 		$1.75M Buy
+50,000
New +$1.26M 0.08% 63

Other funds holding NRIX

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Avidity Partners Management's NRIX Position: Q1 2021 in Review

Avidity Partners Management sold out of Nurix Therapeutics (NRIX) in Q1 2021, closing a stake of 50,000 shares — an estimated $1.64M sold.

Avidity Partners Management first reported a position in NRIX in Q3 2020 and held it in 2 quarters. The position peaked at $1.75M in Q3 2020. 101 funds tracked by Wall St. Rank hold NRIX as of Q1 2021.

  • Avidity Partners Management reported no remaining Nurix Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 50,000 Nurix Therapeutics shares in Q1 2021, an estimated $1.64M.
  • Avidity Partners Management first reported a position in Nurix Therapeutics in Q3 2020 and held it in 2 quarters.
  • Avidity Partners Management's Nurix Therapeutics position peaked at $1.75M in Q3 2020.
  • 101 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.